Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

20104,334 citationsJournal Articlegreen Open Access

Authors

Juan W. Valle · The Christie Hospital

Harpreet Wasan · Hammersmith Hospital

Daniel H. Palmer · NIHR Surgical Reconstruction and Microbiology Research Centre

David Cunningham · Royal Marsden Hospital

Alan Anthoney · St James's University Hospital

Anthony Maraveyas · Castle Hill Hospital

Srinivasan Madhusudan

Abstract

As compared with gemcitabine alone, cisplatin plus gemcitabine was associated with a significant survival advantage without the addition of substantial toxicity. Cisplatin plus gemcitabine is an appropriate option for the treatment of patients with advanced biliary cancer. (ClinicalTrials.gov number, NCT00262769.)

Topics & Keywords

Cholangiocarcinoma and Gallbladder Cancer Studies Gallbladder and Bile Duct Disorders Pancreatic and Hepatic Oncology Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 362, Issue 14, pp. 1273-1281

DOI: 10.1056/nejmoa0908721

Field-Weighted Citation Impact: 118.83